The proactive attitude of governments of many countries in Asia are also leading to the development of the biologics sector. In China, the government is taking significant steps. It invested $100 million in AutekBio to construct a world class R&D and manufacturing center in Beijing for international biologics developments. Genor Biomanufacturing, China, is building a cGMP facilities in Shanghai. Other companies that are planning to build biologics manufacturing facilities in China with over 10,000 litres of bioreactor capacity are Pacific MeinuoKe, Wuxi Pharma, Advanced Biologics and Kanda Biotechnology. China is making a lot of efforts to strengthen their biologics industry and this is evident in the increasing number of approvals being received by China. Furthermore, while Australia spends an estimated $62.4 million annually on payments for contract manufacturing activities, Malaysia is home to two major biologics manufacturers, InnoBio and Alpha Biologics. Singapore has invested heavily in the biologics sector, with A-Bio Pharma developing a GMP manufacturing facility that meets both the US FDA and EU EMEA GMP requirements.

The face of the pharma sector is changing substantially. While PwC says that bioengineered vaccines and biologics will account for 23 percent of the global market by 2016, BMI has projected that contract manufacturing will touch $33.7 billion by 2014. One of the reasons for this growth is the fact that although there are several disadvantages associated with biologics manufacturing, the numerous advantages clearly outwigh them. Moreover, contract and biologics manufacturing business are also offering a lot of value proposition. A recently released index by BioPlan Associates states that China has 8.5 percent, India has eight percent, and Japan and other Asian countries together have 9.2 percent of the world's biomanufacturing potential.

Many first generation biopharmaceuticals products are maturing and there will be more focus on biologics contract manufacturing. The manufacturers need to scale up capabilities, facilities, procedures and resources and most importantly, improve on regulatory compliance.

Must Read>> List of leading biologics manufacturers in Asia Pacific

Must Read>> Break up of top 1000 biopharma companies - country wise